Prepared By
Guided By             Ashvin Rakholiya
Mr. Pravin Mesariya
                       M.Pharm Sem-1
                      Quality Assurance
Contents
 Definition
 History
 General Provisions
 Organization and personnel
 Facilities
 Equipment
 Testing facilities operation
 Test and Control Articles
 Protocol for and Conduct of Nonclinical Study
 Records and Reports
Good Laboratory Practice
 Good Laboratory Practice is a quality system
  concerned with the organizational process and
  the conditions under which a study is planned,
  performed, monitored, recorded, archived and
  reported.

Why GLP?
 Development of quality test data
 Mutual acceptance of data
 Avoid duplication of data
 Avoid technical barriers to trade
 Protection of human health and the
  environment
HISTORY

   Created GLP is a formal regulation that was by the FDA
    (United states food and drug administration) in 1978.

   Although GLP originated in the United States , it had a
    worldwide impact.

   Non-US companies that wanted to do business with the
    United States or register their pharmacies in the United
    States had to comply with the United States GLP
    regulations.
   They eventually started making GLP regulations in
    their home countries.

   In 1981 an organization named OECD (organization for
    economic principles that are international standard.co-
    operation and development) produced GLP
Subpart A - General Provisions

Scope

   This part prescribes good laboratory practices
    for conducting non-clinical laboratory studies
    that support or are intended to support
    applications for research or marketing permits
    for products regulated by the FDA, including
    food and colour additives, animal food
    additives, human and animal drugs, medical
    devices for human use, biological products, and
    electronic products.
Inspection of a testing facility

   A testing facility shall permit an authorised
    employee of the FDA, at reasonable times and
    in a reasonable manner, to inspect the facility
    all records and specimens required to be
    maintained regarding studies within the
    scope of this part..

   If the testing facility refuses to permit
    inspection the Food and Drug administrtion
    will not consider a non-clinical laboratory
    study in support of an application for a
    research or marketing permit.
Subpart B - Organisation and Personnel

Personnel

   Each individual engaged in the conduct of or
    responsible for the supervision of a non-clinical
    laboratory study shall have
    education, training, and experience

   There shall be a sufficient number of personnel
    for the timely and proper conduct of the study
    according to the protocol.

   Personnel shall take necessary personal
    sanitation and health precautions designed to
    avoid contamination of test and control articles
    and test systems.
   Personnel engaged in a non-clinical laboratory study
    shall wear clothing appropriate for the duties they
    perform.

   Any individual found at any time to have an illness
    that may adversely affect the quality and integrity of
    the non-clinical laboratory study shall be excluded
    from direct contact with test systems, test and
    control articles

Testing facility management

    For each non-clinical laboratory study, testing facility
    management shall:

   Replace the study director promptly if it becomes
    necessary to do so during the conduct of a study.
   Assure that test and control articles or
    mixtures have been appropriately tested for
    identity, strength, purity, stability, and
    uniformity, as applicable.

   Assure that
    personnel, resources, facilities, equipment, m
    aterials and methodologies are available as
    scheduled.

   As sure that any deviations from these
    regulations reported by the quality assurance
    unit are communicated to the study director
    and corrective actions are taken and
    documented.
Study director
 For each non-clinical laboratory study, a scientist or other
  professional of appropriate education, training, and
  experience, or combination thereof, shall be identified as
  the study director.

   The study director has overall responsibility for the
    technical conduct of the study, as well as for the
    interpretation, analysis, documentation and reporting of
    the results, and represents the single point of study
    control.

 The study director shall assure that:
 The protocol including any change, is approved and is
  followed. All experimental data, including observations of
  unanticipated response of the test system are accurately
  recorded and verified.

   All applicable good laboratory practice regulations are
    followed.
Quality assurance unit

Responsibilities Of The quality assurance unit

   Monitoring each study to assure management
    that the
    facilities, equipment, personnel, methods, pra
    ctice, records, and controls are in
    conformance with the regulations in this part.

   For any given study, the quality assurance
    unit shall be entirely separate from and
    independent of the personnel engaged in the
    direction and conduct of that study.
Funtions of the quality assurance unit:

   Maintain a copy of a master schedule sheet
   Inspect each non-clinical laboratory study at
    intervals adequate to assure the integrity of the
    study and maintain written and properly signed
    records of each periodic inspection
   Determine that no deviations from approved
    protocols or standing operating procedures were
    made without proper authorisation and
    documentation.
   A designated representative of the FDA shall have
    access to the written procedures established for
    the inspection and may request testing facility
    management to certify that inspections are being
    implemented, performed, documented, and
    followed-up in accordance with this paragraph.
Subpart C – Facilities

 General
 Each testing facility shall be of suitable size
  and construction to facilitate the proper
  conduct of non-clinical laboratory studies. It
  shall be designed so that there is a degree of
  separation that will prevent any further
  function or activity from having an adverse
  effect on the study.

 Animal care facilities
 A testing facility shall have sufficient number
  of animal rooms or areas
   Separate areas shall be provided, as
    proposed, for the diagnosis, treatment, and
    control of laboratory animal disease.

   When animals are housed, facilities shall exist
    for the collection and disposal of all animal
    waste and refuse or for safe sanitary storage
    of waste before removal from the testing
    facility.
Facilities for handling test and control articles

   As necessary to prevent contamination or
    mix-ups, there shall be separate areas for
    Receipt and storage of the test and control
    articles, Mixing of the test and control articles
    with a carrier, Storage of the test and control
    article mixtures.

   Storage areas for the test and or control
    article and test and control mixtures shall be
    separate from areas housing the test systems
    and shall be adequate to preserve the
    identity, strength, purity, and stability of the
    articles and mixtures.
Laboratory operation areas
 Separate laboratory space shall be provided,
  as needed, for performance of the routine
  and specialised procedures required by non-
  clinical laboratory studies.

Specimen and data storage facilities
 Space shall be provided for archives, limited
  access by authorised personnel only, for the
  storage and retrieval of all raw data and
  specimens from completed studies.
Subpart D – Equipment

Equipment design

   Equipment used in the generation, measurement, or
    assessment of data and equipment used for facility
    environmental control shall be of appropriate design and
    adequate capacity to function according to the protocol
    and shall be suitability located for operation, inspection,
    cleaning and maintenance.

Maintenance and calibration of equipment

   Equipment shall be adequately inspected, cleaned, and
    maintained. Equipment used for the generation,
    measurement, or assessment of data shall be adequately
    tested, calibrated or standardised

   Written records shall be maintained of all inspection,
    maintenance, testing, calibration and standardising
    operations.
Subpart E - Testing Facilities Operation

Standard operating procedures.

  Standard operating procedures shall be
  established for
 Animal room preparation.
 Animal care.
 Receipt, identification, storage, handling,
  mixing, and method of sampling of the test
  and control articles.
 Test system observations.
 Laboratory tests.
   Handling of animals found moribund or dead
    during study.
   Necropsy of animals or post mortem
    examination of animals.
   Collection and identification of specimens.
   Histopathology.
   Data handling, storage, and retrieval.
   Maintenance and calibration of equipment.
   Transfer, proper placement, and identification
    of animals.
Reagents and solutions
 All reagents and solutions in the laboratory areas
  shall be labelled to indicate identity, titre or
  concentration, storage requirements, and
  expiration date. Deteriorated or outdated
  reagents and solutions shall not be used.

 Animal care
 There shall be standard operating procedures for
  the housing, feeding, handling, and care of
  animals.
 All newly received animals from outside sources
  shall be isolated and their health status shall be
  evaluated
 At the initiation of a non-clinical laboratory
  study, animals shall be free of any.
   If, during the course of the study, the animals
    contract such a disease or condition, the
    diseased animals shall be isolated, if necessary

   These animals may be treated for disease or
    signs of disease provided that such treatment
    does not interfere with the study.

    The diagnosis, authorisation of
    treatment, description of treatment, and each
    date of treatment shall be documented and shall
    be retained.

   Animals of different species shall be housed in
    separate rooms when necessary..
   Animal cages, racks and accessory equipment
    shall be cleaned and sanitised at appropriate
    intervals.

   Feed and water used for the animals shall be
    analysed periodically to ensure that contaminants
    known to be capable of interfering with study
    and reasonably expected to be present in such
    feed or water are not present in levels above
    those specified in the protocol. Documentation of
    such analyses shall be maintained as raw data.

   If any pest control materials are used, the use
    shall be documented. Cleaning and pest control
    materials that interfere with the study shall not
    be used.
Subpart F - Test and Control Articles

Test and control article characterisation

   The identity, strength, purity, and
    composition or other characteristics which
    will appropriately define the test or control
    article shall be determined for each batch and
    shall be documented.

   Methods of synthesis, fabrication, or
    derivation of the test and control articles shall
    be documented by the sponsor or the testing
    facility.
   Each storage container for a test or control
    article shall be labelled by name, chemical
    abstract number, or code number, batch
    number, expiration date, if
    any, and, and, where appropriate, storage
    conditions necessary to maintain the
    identity, strength, purity, and composition of
    the test or control article. Storage containers
    shall be assigned to a particular test article
    for the duration of the study.
Test and control article handling

    Procedures shall be established for a system for
    the handling of the test and control articles to
    ensure that:
   There is proper storage.
   Distribution is made in a manner designed to
    preclude the possibility of contamination,
    deterioration, or damage.
   Proper identification is maintained throughout
    the distribution process.
   The receipt and distribution of each batch is
    documented. Such documentation shall include
    the date and quantity of each batch distributed
    or returned.
Subpart G - Protocol for and Conduct of a Non-
 clinical Laboratory Study

Protocol
 Each study shall have an approved written
  protocol that clearly indicates the objectives and
  all methods for the conduct of the study.

The protocol shall contain:

   A descriptive title and statement of the purpose
    of the study.
   Identification of the test and control articles by
    name, chemical abstract number, or code
    number.
   The name of the sponsor and address of the
    testing facility
   The number, body weight range, sex, source
    of supply, species, strain, sub strain, and age
    of the test system.

   The procedure for the identification of the
    system.

   A description of the experimental design,
    including the methods for the control bias.

   Each dosage level to be administered and the
    method and frequency of administration.

   The records to be maintained.
Conduct of nonclinical laboratory study.

   The non-clinical laboratory study shall be
    conducted in accordance with the protocol.

   The systems shall be monitored in conformity
    with the protocol.

   Specimens shall be identified by test system,
    study, nature, and date of collection.
   Records of gross findings for a specimen
    from post-mortem observations should be
    available to a pathologist when examining
    that specimen histopathologically.

   Any change in these entries shall be made so
    as not to obscure the original entry, shall
    indicate the reason for such change, and shall
    be dated and signed or identified at the time
    of the change.
Subparts J- Records and Reports

Reporting of non-clinical laboratory study results.

      A final report shall be prepared for each non-
    clinical laboratory study and shall include

   Name and address of the facility performing the
    study and the dates

   Statistical methods employed for analysing data.

   The test and control articles identified by name,
    code number, strength, purity, and composition
    or other characteristics.
   Stability of the test and control articles under
    the conditions of administration.

   A description of the methods used.

   A description of the test system used.

   A description of the dosage, dosage regimen,
    route of administration, and duration.

   The name of the study director, other
    scientists, supervisory personnel involved in
    the study.
   A description of the
    transformations, calculations, or operations
    performed on the data, a summary and
    analysis of the data, and a statement of the
    conclusions drawn from the analysis.

   The locations where all specimens, raw
    data, and the final report are to be stored.

   The statement prepared and signed by the
    quality assurance Unit.
   The final report shall be signed and dated by
    the study director.

   Corrections or additions to a final report shall
    be in the form of an amendment by the study
    director. The amendment shall clearly identify
    that part of the report that is being added to
    or corrected and the reasons for the
    correction or addition, and shall be signed
    and dated by the person responsible.
Storage and retrieval of records and data

   All raw data, documentation, protocols, final
    reports, and generated as a result of a non-
    clinical laboratory study shall be retained.

   There shall be archives for orderly storage
    and expedient retrieval of all raw
    data, documentation, protocols, specimens, a
    nd interim and final reports.
   An individual shall be identified as being
    responsible for the archives.

   Only authorised personnel shall enter the
    archives.

   Material retained or referred to in the archives
    shall be indexed to permit expedient retrieval
REFERENCES

   How to practice GLP by p.p. Sharma, 2nd
    edition:2008
    http://www.oecd.org under environment
    chemical safety
   http://europa.eu.in

More Related Content

PPTX
ICH Guidelines
PPTX
FACTORS AFFECTING FLUORESCENCE INTENSITY.pptx
PPTX
Quality control test: Containers, Closures and Secondary packing materials
PPTX
Documentation In Pharmaceutical Industry.pptx
PPTX
Chronopharmacology
PPTX
Quality Assurance and Quality Management Concepts
PPTX
COMPLAINTS. UNIT IV
PDF
Platform technology
ICH Guidelines
FACTORS AFFECTING FLUORESCENCE INTENSITY.pptx
Quality control test: Containers, Closures and Secondary packing materials
Documentation In Pharmaceutical Industry.pptx
Chronopharmacology
Quality Assurance and Quality Management Concepts
COMPLAINTS. UNIT IV
Platform technology

What's hot (20)

PPTX
ICH QSEM Guidelines
PDF
Document Maintenance in Pharmaceutical Industry
PPTX
Quality Control tests for pharmaceutical containers, closures and secondary p...
PDF
PPTX
GOOD LABORATORY PRACTICES - A DETAILED STUDY
PPTX
Pharmaceutical validation, calibration & qualifications
PPTX
ORGANISATION and PERSONNEL
PPTX
Distribution records
PPTX
BATCH MANUFACTURING RECORD
PDF
General Principles of Analytical Method of Validation.pdf
PPTX
Complaints (QUALITY ASSURANCE)
PPTX
Pharmaceutical validation & it's types
PPTX
calibration-and-validation
PPTX
Master formula record
PPSX
Qualification of UV VISIBLE SPECTROPHOTOMETER
PDF
ISO9000 & ISO14000, B.PHARMACY, 6TH SEM,PHARMACEUTICAL QUALITY ASSURANCE, UNIT-I
PPTX
Unit 4 Document maintenance in Pharmaceutical Industry.pptx
PPTX
Premises - Part of Good Manufacturing Practices
PPTX
Good laboratory practices of pharmaceuticals
PPTX
Documentation in pharmaceutical industry
ICH QSEM Guidelines
Document Maintenance in Pharmaceutical Industry
Quality Control tests for pharmaceutical containers, closures and secondary p...
GOOD LABORATORY PRACTICES - A DETAILED STUDY
Pharmaceutical validation, calibration & qualifications
ORGANISATION and PERSONNEL
Distribution records
BATCH MANUFACTURING RECORD
General Principles of Analytical Method of Validation.pdf
Complaints (QUALITY ASSURANCE)
Pharmaceutical validation & it's types
calibration-and-validation
Master formula record
Qualification of UV VISIBLE SPECTROPHOTOMETER
ISO9000 & ISO14000, B.PHARMACY, 6TH SEM,PHARMACEUTICAL QUALITY ASSURANCE, UNIT-I
Unit 4 Document maintenance in Pharmaceutical Industry.pptx
Premises - Part of Good Manufacturing Practices
Good laboratory practices of pharmaceuticals
Documentation in pharmaceutical industry
Ad

Similar to Glp 112070804004 (20)

PPTX
GOOD LABORATORY PRACTICES(GLP).pptx
PPTX
OECD principles of Good Laboratory Practice.
PPTX
Good laboratory practice
PPSX
GLP 21 CFR part 58
PPTX
USFDA guidelines of glp for non clinical testing laboratories
PPTX
Good Laboratory Practices Mubashir Maqbool
PPTX
OECD Principle Of Good Laboratory Practice (GLP).pptx
PPTX
Quality Assurance Good laboratory practice P25.pptx
PPTX
Good laboratory practices.pptx
PPTX
Good Laboratory Practices .pptx
PPTX
GLP.pptx
PPTX
Good Laboratory Practice (GLP)
PPTX
Good laboratory practices.pptx
PPTX
Good laboratory practices
PPT
Good laboratory practices
PPTX
Glp seminar
PPT
Good laboratory practices (GLP) himanshu
PPTX
PQA-Unit 3-GOOD LABORATORY PRACTICE.pptx
GOOD LABORATORY PRACTICES(GLP).pptx
OECD principles of Good Laboratory Practice.
Good laboratory practice
GLP 21 CFR part 58
USFDA guidelines of glp for non clinical testing laboratories
Good Laboratory Practices Mubashir Maqbool
OECD Principle Of Good Laboratory Practice (GLP).pptx
Quality Assurance Good laboratory practice P25.pptx
Good laboratory practices.pptx
Good Laboratory Practices .pptx
GLP.pptx
Good Laboratory Practice (GLP)
Good laboratory practices.pptx
Good laboratory practices
Good laboratory practices
Glp seminar
Good laboratory practices (GLP) himanshu
PQA-Unit 3-GOOD LABORATORY PRACTICE.pptx
Ad

More from Patel Parth (20)

PPT
Automated analysis by yatin sankharva copy
PPT
Automated analysis 112070804013
PPT
Anda registration in us eu
PPTX
Anda ppt
PPTX
Analytical tech in pre formulation 112070804009
PPTX
Analysis of solid oral
PPTX
Analysis of solid oral dosage forms 112070804010
PPTX
Analysis of parenteral dosage forms bjl final seminar
PPTX
Analysis of data (pratik)
PPTX
Analysis of cosmetics 112070804018
PPT
Agencies dhwani
PPTX
A seminar on applications of various analytical technique
PPT
23117 copy of oral solid dosage forms
PPTX
4016 solid state analysis
PPT
4003 regulatory aspect_of_bulk,pharmaceutical,biotech
PPTX
A.a sequence analysis 112070804002
PPTX
Chi square test
PPTX
Sterility testing 112070804014
PPT
Ria 112070804007
PPTX
Qc lab 112070804001
Automated analysis by yatin sankharva copy
Automated analysis 112070804013
Anda registration in us eu
Anda ppt
Analytical tech in pre formulation 112070804009
Analysis of solid oral
Analysis of solid oral dosage forms 112070804010
Analysis of parenteral dosage forms bjl final seminar
Analysis of data (pratik)
Analysis of cosmetics 112070804018
Agencies dhwani
A seminar on applications of various analytical technique
23117 copy of oral solid dosage forms
4016 solid state analysis
4003 regulatory aspect_of_bulk,pharmaceutical,biotech
A.a sequence analysis 112070804002
Chi square test
Sterility testing 112070804014
Ria 112070804007
Qc lab 112070804001

Glp 112070804004

  • 1. Prepared By Guided By Ashvin Rakholiya Mr. Pravin Mesariya M.Pharm Sem-1 Quality Assurance
  • 2. Contents  Definition  History  General Provisions  Organization and personnel  Facilities  Equipment  Testing facilities operation  Test and Control Articles  Protocol for and Conduct of Nonclinical Study  Records and Reports
  • 3. Good Laboratory Practice  Good Laboratory Practice is a quality system concerned with the organizational process and the conditions under which a study is planned, performed, monitored, recorded, archived and reported. Why GLP?  Development of quality test data  Mutual acceptance of data  Avoid duplication of data  Avoid technical barriers to trade  Protection of human health and the environment
  • 4. HISTORY  Created GLP is a formal regulation that was by the FDA (United states food and drug administration) in 1978.  Although GLP originated in the United States , it had a worldwide impact.  Non-US companies that wanted to do business with the United States or register their pharmacies in the United States had to comply with the United States GLP regulations.
  • 5. They eventually started making GLP regulations in their home countries.  In 1981 an organization named OECD (organization for economic principles that are international standard.co- operation and development) produced GLP
  • 6. Subpart A - General Provisions Scope  This part prescribes good laboratory practices for conducting non-clinical laboratory studies that support or are intended to support applications for research or marketing permits for products regulated by the FDA, including food and colour additives, animal food additives, human and animal drugs, medical devices for human use, biological products, and electronic products.
  • 7. Inspection of a testing facility  A testing facility shall permit an authorised employee of the FDA, at reasonable times and in a reasonable manner, to inspect the facility all records and specimens required to be maintained regarding studies within the scope of this part..  If the testing facility refuses to permit inspection the Food and Drug administrtion will not consider a non-clinical laboratory study in support of an application for a research or marketing permit.
  • 8. Subpart B - Organisation and Personnel Personnel  Each individual engaged in the conduct of or responsible for the supervision of a non-clinical laboratory study shall have education, training, and experience  There shall be a sufficient number of personnel for the timely and proper conduct of the study according to the protocol.  Personnel shall take necessary personal sanitation and health precautions designed to avoid contamination of test and control articles and test systems.
  • 9. Personnel engaged in a non-clinical laboratory study shall wear clothing appropriate for the duties they perform.  Any individual found at any time to have an illness that may adversely affect the quality and integrity of the non-clinical laboratory study shall be excluded from direct contact with test systems, test and control articles Testing facility management For each non-clinical laboratory study, testing facility management shall:  Replace the study director promptly if it becomes necessary to do so during the conduct of a study.
  • 10. Assure that test and control articles or mixtures have been appropriately tested for identity, strength, purity, stability, and uniformity, as applicable.  Assure that personnel, resources, facilities, equipment, m aterials and methodologies are available as scheduled.  As sure that any deviations from these regulations reported by the quality assurance unit are communicated to the study director and corrective actions are taken and documented.
  • 11. Study director  For each non-clinical laboratory study, a scientist or other professional of appropriate education, training, and experience, or combination thereof, shall be identified as the study director.  The study director has overall responsibility for the technical conduct of the study, as well as for the interpretation, analysis, documentation and reporting of the results, and represents the single point of study control. The study director shall assure that:  The protocol including any change, is approved and is followed. All experimental data, including observations of unanticipated response of the test system are accurately recorded and verified.  All applicable good laboratory practice regulations are followed.
  • 12. Quality assurance unit Responsibilities Of The quality assurance unit  Monitoring each study to assure management that the facilities, equipment, personnel, methods, pra ctice, records, and controls are in conformance with the regulations in this part.  For any given study, the quality assurance unit shall be entirely separate from and independent of the personnel engaged in the direction and conduct of that study.
  • 13. Funtions of the quality assurance unit:  Maintain a copy of a master schedule sheet  Inspect each non-clinical laboratory study at intervals adequate to assure the integrity of the study and maintain written and properly signed records of each periodic inspection  Determine that no deviations from approved protocols or standing operating procedures were made without proper authorisation and documentation.  A designated representative of the FDA shall have access to the written procedures established for the inspection and may request testing facility management to certify that inspections are being implemented, performed, documented, and followed-up in accordance with this paragraph.
  • 14. Subpart C – Facilities General  Each testing facility shall be of suitable size and construction to facilitate the proper conduct of non-clinical laboratory studies. It shall be designed so that there is a degree of separation that will prevent any further function or activity from having an adverse effect on the study. Animal care facilities  A testing facility shall have sufficient number of animal rooms or areas
  • 15. Separate areas shall be provided, as proposed, for the diagnosis, treatment, and control of laboratory animal disease.  When animals are housed, facilities shall exist for the collection and disposal of all animal waste and refuse or for safe sanitary storage of waste before removal from the testing facility.
  • 16. Facilities for handling test and control articles  As necessary to prevent contamination or mix-ups, there shall be separate areas for Receipt and storage of the test and control articles, Mixing of the test and control articles with a carrier, Storage of the test and control article mixtures.  Storage areas for the test and or control article and test and control mixtures shall be separate from areas housing the test systems and shall be adequate to preserve the identity, strength, purity, and stability of the articles and mixtures.
  • 17. Laboratory operation areas  Separate laboratory space shall be provided, as needed, for performance of the routine and specialised procedures required by non- clinical laboratory studies. Specimen and data storage facilities  Space shall be provided for archives, limited access by authorised personnel only, for the storage and retrieval of all raw data and specimens from completed studies.
  • 18. Subpart D – Equipment Equipment design  Equipment used in the generation, measurement, or assessment of data and equipment used for facility environmental control shall be of appropriate design and adequate capacity to function according to the protocol and shall be suitability located for operation, inspection, cleaning and maintenance. Maintenance and calibration of equipment  Equipment shall be adequately inspected, cleaned, and maintained. Equipment used for the generation, measurement, or assessment of data shall be adequately tested, calibrated or standardised  Written records shall be maintained of all inspection, maintenance, testing, calibration and standardising operations.
  • 19. Subpart E - Testing Facilities Operation Standard operating procedures. Standard operating procedures shall be established for  Animal room preparation.  Animal care.  Receipt, identification, storage, handling, mixing, and method of sampling of the test and control articles.  Test system observations.  Laboratory tests.
  • 20. Handling of animals found moribund or dead during study.  Necropsy of animals or post mortem examination of animals.  Collection and identification of specimens.  Histopathology.  Data handling, storage, and retrieval.  Maintenance and calibration of equipment.  Transfer, proper placement, and identification of animals.
  • 21. Reagents and solutions  All reagents and solutions in the laboratory areas shall be labelled to indicate identity, titre or concentration, storage requirements, and expiration date. Deteriorated or outdated reagents and solutions shall not be used. Animal care  There shall be standard operating procedures for the housing, feeding, handling, and care of animals.  All newly received animals from outside sources shall be isolated and their health status shall be evaluated  At the initiation of a non-clinical laboratory study, animals shall be free of any.
  • 22. If, during the course of the study, the animals contract such a disease or condition, the diseased animals shall be isolated, if necessary  These animals may be treated for disease or signs of disease provided that such treatment does not interfere with the study.  The diagnosis, authorisation of treatment, description of treatment, and each date of treatment shall be documented and shall be retained.  Animals of different species shall be housed in separate rooms when necessary..
  • 23. Animal cages, racks and accessory equipment shall be cleaned and sanitised at appropriate intervals.  Feed and water used for the animals shall be analysed periodically to ensure that contaminants known to be capable of interfering with study and reasonably expected to be present in such feed or water are not present in levels above those specified in the protocol. Documentation of such analyses shall be maintained as raw data.  If any pest control materials are used, the use shall be documented. Cleaning and pest control materials that interfere with the study shall not be used.
  • 24. Subpart F - Test and Control Articles Test and control article characterisation  The identity, strength, purity, and composition or other characteristics which will appropriately define the test or control article shall be determined for each batch and shall be documented.  Methods of synthesis, fabrication, or derivation of the test and control articles shall be documented by the sponsor or the testing facility.
  • 25. Each storage container for a test or control article shall be labelled by name, chemical abstract number, or code number, batch number, expiration date, if any, and, and, where appropriate, storage conditions necessary to maintain the identity, strength, purity, and composition of the test or control article. Storage containers shall be assigned to a particular test article for the duration of the study.
  • 26. Test and control article handling Procedures shall be established for a system for the handling of the test and control articles to ensure that:  There is proper storage.  Distribution is made in a manner designed to preclude the possibility of contamination, deterioration, or damage.  Proper identification is maintained throughout the distribution process.  The receipt and distribution of each batch is documented. Such documentation shall include the date and quantity of each batch distributed or returned.
  • 27. Subpart G - Protocol for and Conduct of a Non- clinical Laboratory Study Protocol  Each study shall have an approved written protocol that clearly indicates the objectives and all methods for the conduct of the study. The protocol shall contain:  A descriptive title and statement of the purpose of the study.  Identification of the test and control articles by name, chemical abstract number, or code number.  The name of the sponsor and address of the testing facility
  • 28. The number, body weight range, sex, source of supply, species, strain, sub strain, and age of the test system.  The procedure for the identification of the system.  A description of the experimental design, including the methods for the control bias.  Each dosage level to be administered and the method and frequency of administration.  The records to be maintained.
  • 29. Conduct of nonclinical laboratory study.  The non-clinical laboratory study shall be conducted in accordance with the protocol.  The systems shall be monitored in conformity with the protocol.  Specimens shall be identified by test system, study, nature, and date of collection.
  • 30. Records of gross findings for a specimen from post-mortem observations should be available to a pathologist when examining that specimen histopathologically.  Any change in these entries shall be made so as not to obscure the original entry, shall indicate the reason for such change, and shall be dated and signed or identified at the time of the change.
  • 31. Subparts J- Records and Reports Reporting of non-clinical laboratory study results. A final report shall be prepared for each non- clinical laboratory study and shall include  Name and address of the facility performing the study and the dates  Statistical methods employed for analysing data.  The test and control articles identified by name, code number, strength, purity, and composition or other characteristics.
  • 32. Stability of the test and control articles under the conditions of administration.  A description of the methods used.  A description of the test system used.  A description of the dosage, dosage regimen, route of administration, and duration.  The name of the study director, other scientists, supervisory personnel involved in the study.
  • 33. A description of the transformations, calculations, or operations performed on the data, a summary and analysis of the data, and a statement of the conclusions drawn from the analysis.  The locations where all specimens, raw data, and the final report are to be stored.  The statement prepared and signed by the quality assurance Unit.
  • 34. The final report shall be signed and dated by the study director.  Corrections or additions to a final report shall be in the form of an amendment by the study director. The amendment shall clearly identify that part of the report that is being added to or corrected and the reasons for the correction or addition, and shall be signed and dated by the person responsible.
  • 35. Storage and retrieval of records and data  All raw data, documentation, protocols, final reports, and generated as a result of a non- clinical laboratory study shall be retained.  There shall be archives for orderly storage and expedient retrieval of all raw data, documentation, protocols, specimens, a nd interim and final reports.
  • 36. An individual shall be identified as being responsible for the archives.  Only authorised personnel shall enter the archives.  Material retained or referred to in the archives shall be indexed to permit expedient retrieval
  • 37. REFERENCES  How to practice GLP by p.p. Sharma, 2nd edition:2008  http://www.oecd.org under environment chemical safety  http://europa.eu.in